Oncolytics Biotech Inc. (ONCY)
- Previous Close
0.3644 - Open
0.3800 - Bid 0.2555 x 200
- Ask 0.4420 x 200
- Day's Range
0.3390 - 0.3800 - 52 Week Range
0.3390 - 1.5300 - Volume
932,856 - Avg. Volume
469,641 - Market Cap (intraday)
30.2M - Beta (5Y Monthly) 1.50
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2700 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.07
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
oncolyticsbiotech.comRecent News: ONCY
View MorePerformance Overview: ONCY
Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONCY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONCY
View MoreValuation Measures
Market Cap
29.59M
Enterprise Value
19.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-76.34%
Return on Equity (ttm)
-213.85%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-31.5M
Diluted EPS (ttm)
-0.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
15.3M
Total Debt/Equity (mrq)
15.40%
Levered Free Cash Flow (ttm)
-15.09M